// App-Quantinova.ai

: Malignancy Rates Through 5 Years of Follow-up in Guselkumab-treated Patients With Moderate to Severe Psoriasis: Results From the VOYAGE 1 and 2 Trials and Comparisons to General Populations

Researchers

Presenter

  • Andrew Blauvelt

Principal Investigators

  • Richard G. Langley

  • Vincent Ho

  • Katelyn Rowl

  • Daphne Chan

  • Megan Miller

  • Yin You

  • Jenny Yu

  • Ya-Wen Yang

  • Mark Lebwohl

Medical Centers

  • N/A

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

  • Dermatology

Disease

  • Cervical cancer

  • Psoriasis

  • Solid malignancies

  • Systemic inflammatory response syndrome

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved